A low‑priced generic drug already stocked in pharmacies is emerging as a candidate treatment for autism, and it is not leucovorin. Early clinical data suggest measurable gains in social communication and reduced repetitive behaviors, reviving the case for drug repurposing as a shortcut around the usual development entropy in neuropsychiatry.

Researchers are testing the compound in controlled trials after noticing signals in real‑world prescribing data. Because the molecule already has a safety dossier and established pharmacokinetics, regulators can focus on dose–response curves and effect size rather than basic toxicology, changing the marginal effect of each additional study participant. The working hypothesis points to modulation of synaptic plasticity and gamma‑aminobutyric acid signaling, with secondary effects on cortical excitatory–inhibitory balance that map onto long‑standing theories of autism spectrum biology.

The drug’s low manufacturing cost and wide availability raise questions not only about how quickly such evidence can be translated into guidelines, but also about who will fund large, definitive trials when no single company holds a lucrative patent. Between a crowded landscape of small, inconclusive studies and families searching for any data‑driven option, the quiet progress of one cheap pill may become a test of how the medical system values proof over branding.